Floatz logo

rAd-p53

Advanced Adult Hepatocellular Carcinoma

Shenzhen SiBiono GeneTech Co.,LtdPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Advanced Adult Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Roswell Park Cancer Institute
Phase 3BBB
Irinotecan
University of Chicago
Phase 2BB
Inno-206
Case Comprehensive Cancer Center
Phase 3BB
Eloxatin
Case Comprehensive Cancer Center
Phase 2BB
Cixutumumab
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

rAd-p53 is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
diabetes mellitusDormant
CCC
Indicative ·
53 / 100
View asset →
Metastatic Solid Tumor CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →